Key result
In a population pharmacokinetic model of 26 hypertensive children, increasing age had minimal influence on the body size-dependent clearance of valsartan after adjusting for fat-free mass.
Why the study?
What is the population pharmacokinetics of valsartan and the influence of covariates in hypertensive children?
What is the population pharmacokinetics of valsartan and the influence of covariates in hypertensive children?
In hypertensive children, the clearance of valsartan is primarily dependent on body size (fat free mass) rather than age.
Answers are grounded in this paper and cite their sources.
Fat-free mass may inform valsartan dosing in hypertensive children; leaves open prospective validation in larger cohorts.
The objective of this work was to develop a population pharmacokinetic model to assess the influence of subject covariates on the pharmacokinetics of valsartan in children. Data were collected from a single dose study in 26 hypertensive children ages 1 to 16 years. Subjects received 2 mg/kg valsartan suspension up to a maximum dose of 80 mg. Plasma samples were collected and analyzed using LC/MS/MS. Several structural pharmacokinetic models were evaluated for appropriateness. Allometric scaling and standard covariate analyses were performed to explain interindividual variabilities. Objective function values and goodness of fit plots were used for model selection. A posterior predictive check was used for model evaluation. A linear 2-compartment first-order elimination model with zero-order absorption and lag-time best described the disposition of valsartan. Allometric scaling and standard covariate analysis revealed that age and body size have similar influence; however, after adjustment for body size using fat free mass (FFM), the effect of increasing age was no longer significant on valsartan clearance (2% per year relative to a typical 8 year old with FFM of 30 kg). The population pharmacokinetic model reveals that increase in age has minimal influence on body size dependent clearance of valsartan in children.
No takes yet. Share an insight, caveat, or question.
Habtemariam et al. (2009) studied Hypertension (n=26). Valsartan was evaluated on Valsartan clearance. In a population pharmacokinetic model of 26 hypertensive children, increasing age had minimal influence on the body size-dependent clearance of valsartan after adjusting for fat-free mass.
Synapse has enriched 10 related papers. Consider them for comparative context: